EP4525878A4 - Pharmazeutische zusammensetzungen mit meloxicam - Google Patents
Pharmazeutische zusammensetzungen mit meloxicamInfo
- Publication number
- EP4525878A4 EP4525878A4 EP23808571.6A EP23808571A EP4525878A4 EP 4525878 A4 EP4525878 A4 EP 4525878A4 EP 23808571 A EP23808571 A EP 23808571A EP 4525878 A4 EP4525878 A4 EP 4525878A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- containing meloxicam
- meloxicam
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263343982P | 2022-05-19 | 2022-05-19 | |
| PCT/US2023/067172 WO2023225596A1 (en) | 2022-05-19 | 2023-05-18 | Pharmaceutical compositions comprising meloxicam |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4525878A1 EP4525878A1 (de) | 2025-03-26 |
| EP4525878A4 true EP4525878A4 (de) | 2026-05-13 |
Family
ID=88792615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP23808571.6A Pending EP4525878A4 (de) | 2022-05-19 | 2023-05-18 | Pharmazeutische zusammensetzungen mit meloxicam |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20230372355A1 (de) |
| EP (1) | EP4525878A4 (de) |
| JP (1) | JP2025517771A (de) |
| KR (1) | KR20250012118A (de) |
| CN (1) | CN119451680A (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12485176B2 (en) | 2015-02-10 | 2025-12-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11617791B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US20240058354A1 (en) | 2020-04-06 | 2024-02-22 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12128052B2 (en) | 2020-05-28 | 2024-10-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12370196B2 (en) | 2020-12-31 | 2025-07-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12005118B2 (en) | 2022-05-19 | 2024-06-11 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| AU2024330673A1 (en) * | 2023-08-31 | 2026-03-05 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12544383B1 (en) | 2025-01-30 | 2026-02-10 | Axsome Therapeutics, Inc. | Methods of treating migraines with a combination of a meloxicam and a rizatriptan |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200179396A1 (en) * | 2017-01-04 | 2020-06-11 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US20200254097A1 (en) * | 2015-02-10 | 2020-08-13 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10758617B2 (en) * | 2017-06-29 | 2020-09-01 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10933137B2 (en) * | 2015-02-10 | 2021-03-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11110173B2 (en) * | 2015-02-10 | 2021-09-07 | Axsome Therapeutics, Inc | Pharmaceutical compositions comprising meloxicam |
| US11207327B2 (en) * | 2017-01-04 | 2021-12-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11712441B2 (en) * | 2017-06-29 | 2023-08-01 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
-
2023
- 2023-05-18 CN CN202380047596.8A patent/CN119451680A/zh active Pending
- 2023-05-18 KR KR1020247042047A patent/KR20250012118A/ko active Pending
- 2023-05-18 JP JP2024568630A patent/JP2025517771A/ja active Pending
- 2023-05-18 EP EP23808571.6A patent/EP4525878A4/de active Pending
- 2023-05-24 US US18/323,040 patent/US20230372355A1/en not_active Abandoned
-
2024
- 2024-11-18 US US18/950,743 patent/US20250195534A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200254097A1 (en) * | 2015-02-10 | 2020-08-13 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10933137B2 (en) * | 2015-02-10 | 2021-03-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11110173B2 (en) * | 2015-02-10 | 2021-09-07 | Axsome Therapeutics, Inc | Pharmaceutical compositions comprising meloxicam |
| US20200179396A1 (en) * | 2017-01-04 | 2020-06-11 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11207327B2 (en) * | 2017-01-04 | 2021-12-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10758617B2 (en) * | 2017-06-29 | 2020-09-01 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2023225596A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230372355A1 (en) | 2023-11-23 |
| EP4525878A1 (de) | 2025-03-26 |
| JP2025517771A (ja) | 2025-06-10 |
| US20250195534A1 (en) | 2025-06-19 |
| KR20250012118A (ko) | 2025-01-23 |
| CN119451680A (zh) | 2025-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4271386A4 (de) | Pharmazeutische zusammensetzungen mit meloxicam | |
| EP4563151A4 (de) | Pharmazeutische zusammensetzung mit kras-g12d-inhibitor | |
| EP4221690A4 (de) | Pharmazeutische zusammensetzungen | |
| EP4045480A4 (de) | Pharmazeutische formulierungen | |
| EP3621621C0 (de) | Pharmazeutische zusammensetzungen mit meloxicam | |
| EP4072520C0 (de) | Pharmazeutische zusammensetzungen mit cabotegravir | |
| EP4135699A4 (de) | Pharmazeutische zusammensetzungen | |
| EP4122483A4 (de) | Orale pharmazeutische zusammensetzung | |
| EP3784214C0 (de) | Flüssige orale pharmazeutische darreichungsform | |
| EP4037659C0 (de) | Pharmazeutische zusammensetzung mit enzalutamid | |
| EP4361174A4 (de) | Acylierte insulinhaltige pharmazeutische zusammensetzung | |
| EP4410292A4 (de) | Pharmazeutische zusammensetzung mit triazinderivat | |
| EP4015001A4 (de) | Orale pharmazeutische zusammensetzung | |
| EP4225278A4 (de) | Pharmazeutische zusammensetzung aus siglec-bindenden mitteln | |
| EP4616860A4 (de) | Pharmazeutische zusammensetzung mit aak1-inhibitor | |
| EP4456887A4 (de) | Pharmazeutische zusammensetzung | |
| EP3813822A4 (de) | Feste orale pharmazeutische zusammensetzungen mit teriflunomid | |
| EP4479041A4 (de) | Multimerisierende pharmazeutische zusammensetzungen | |
| EP4257603A4 (de) | Pharmazeutische zusammensetzung mit anti-verbindungsivem gewebewachstumsfaktor-antikörper | |
| EP4326280A4 (de) | Pharmazeutische zusammensetzungen mit picroside | |
| EP4349366A4 (de) | Pharmazeutische zusammensetzung | |
| EP4447932A4 (de) | Pharmazeutische clozapinzusammensetzung mit verlängerter freisetzung | |
| EP4268830A4 (de) | Pharmazeutische zusammensetzung | |
| EP4265253A4 (de) | Pharmazeutische zusammensetzung | |
| EP4265252A4 (de) | Pharmazeutische zusammensetzung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20241219 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AXSOME THERAPEUTICS, INC. |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TABUTEAU, HERRIOT |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40126184 Country of ref document: HK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20260413 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/5415 20060101AFI20260407BHEP Ipc: A61K 31/4196 20060101ALI20260407BHEP Ipc: A61K 9/00 20060101ALI20260407BHEP Ipc: A61K 47/02 20060101ALI20260407BHEP Ipc: A61K 47/69 20170101ALI20260407BHEP Ipc: A61P 25/06 20060101ALI20260407BHEP Ipc: A61P 29/00 20060101ALI20260407BHEP Ipc: A61K 9/20 20060101ALI20260407BHEP Ipc: A61K 9/46 20060101ALI20260407BHEP Ipc: A61K 9/24 20060101ALI20260407BHEP Ipc: A61K 31/4439 20060101ALI20260407BHEP Ipc: A61K 31/724 20060101ALI20260407BHEP Ipc: A61P 25/00 20060101ALI20260407BHEP Ipc: C08B 37/16 20060101ALI20260407BHEP Ipc: C08L 5/16 20060101ALI20260407BHEP |